Please use this identifier to cite or link to this item:
|Title:||Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury||Authors:||Shakkour, Zaynab
Habashy, Karl John
|Keywords:||Traumatic Brain Injury (TBI)
Amyotrophic lateral sclerosis
|Issue Date:||2021||Part of:||Current Medicinal Chemistry||Volume:||28||Issue:||12||Start page:||1||End page:||23||Abstract:||
Edaravone is a potent free-radical scavenger that has been in the market for more than 30 years. It was originally developed in Japan to treat strokes and has been used there since 2001. Aside from its anti-oxidative effects, edaravone demonstrated beneficial effects on proinflammatory responses, nitric oxide production, and apoptotic cell death. Interestingly, edaravone has shown neuroprotective effects in several animal models of diseases other than stroke. In particular, edaravone administration was found to be effective in halting amyotrophic lateral sclerosis (ALS) progression during the early stages. Accordingly, after its success in Phase III clinical studies, edaravone has been approved by the FDA as a treatment for ALS patients. Considering its promises in neurological disorders and its safety in patients, edaravone is a drug of interest that can be repurposed for traumatic brain injury (TBI) treatment. Drug repurposing is a novel approach in drug development that identifies drugs for purposes other than their original indication. This review presents the biochemical properties of edaravone along with its effects on several neurological disorders in the hope that it can be adopted for treating TBI patients.
|Appears in Collections:||Department of Biology|
Show full item record
checked on Oct 16, 2021
checked on Oct 22, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.